Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Oncolytics Biotech (ONCY) Reports Q3 Loss of $0.16
November 11, 2020 4:52 PM ESTOncolytics Biotech (NASDAQ: ONCY) reported Q3 EPS of ($0.16), versus ($0.16) reported last year.
Financial Highlights
As of September 30, 2020, the Company reported $26.7 million in cash and cash equivalents. The Company raised $3.6 million during the third quarter through the issuing of common stock through our ATM facility.Operating expense for the third quarter of 2020 was $2.5 million, compared to $1.8 million in the third quarter of 2019.R&D expense for the third quarter of 2020 was $3.9 million, compared to $1.7 million in the third quarter of 2019.Net cash used in operating activities for the third... More